Journal of opioid management · 2025
Variation in naloxone and buprenorphine prescribing in LA County's safety-net system.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Pak Lia, Crowley Christina, Ragins Kyle, Belani Hrishikesh, Kalmin Mariah, Watkins Katherine E
Аннотация
OBJECTIVE: To describe patients and visits with identified, probable opioid use disorder (OUD) in Los Angeles County's (LAC) safety-net system and examine rates of naloxone and buprenorphine prescribing across healthcare settings.
DESIGN: A descriptive analysis of electronic health record data.
SETTING: LAC's largest safety-net provider, the LAC Department of Health Services.
PATIENTS: This study included 3,881 patients with 5,580 visits involving probable OUD from July 2022 to June 2023.
MAIN OUTCOME MEASURES: Visit-level analysis was performed to identify treatment settings where patients accessed care. We compared rates of buprenorphine and naloxone prescription across treatment settings using Chi-square tests and 95 percent confidence intervals.
RESULTS: Visits with identified OUD most often occurred in outpatient settings (36 percent) compared to inpatient (31 percent), emergency (24 percent), or urgent care (8 percent) settings. Overall, 35.8 percent of visits included a naloxone prescription, and 30.4 percent included a buprenorphine prescription. Prescription rates varied significantly by treatment setting.
CONCLUSIONS: Most visits with probable OUD did not include naloxone or buprenorphine prescriptions, and prescription receipt varied by setting.
DESIGN: A descriptive analysis of electronic health record data.
SETTING: LAC's largest safety-net provider, the LAC Department of Health Services.
PATIENTS: This study included 3,881 patients with 5,580 visits involving probable OUD from July 2022 to June 2023.
MAIN OUTCOME MEASURES: Visit-level analysis was performed to identify treatment settings where patients accessed care. We compared rates of buprenorphine and naloxone prescription across treatment settings using Chi-square tests and 95 percent confidence intervals.
RESULTS: Visits with identified OUD most often occurred in outpatient settings (36 percent) compared to inpatient (31 percent), emergency (24 percent), or urgent care (8 percent) settings. Overall, 35.8 percent of visits included a naloxone prescription, and 30.4 percent included a buprenorphine prescription. Prescription rates varied significantly by treatment setting.
CONCLUSIONS: Most visits with probable OUD did not include naloxone or buprenorphine prescriptions, and prescription receipt varied by setting.